Experienced in Acute Intermittent Porphyria

Dr. Benjamin K. Tomlinson

Hematology Oncology | Hematology | Oncology
University Hospitals Medical Group, Inc.
11100 Euclid Ave, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
16 Years of Experience
Experienced in Acute Intermittent Porphyria
University Hospitals Medical Group, Inc.
11100 Euclid Ave, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Benjamin Tomlinson is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Tomlinson has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Acute Intermittent Porphyria. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Tomlinson is currently accepting new patients.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Hematology Oncology
Hematology
Oncology
Hospital Affiliations
Uh Cleveland Medical Center
Uh Regional Hospitals
Uh St John Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Primetime Health Plan
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE PART D
SummaCare
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

UNIVERSITY HOSPITALS MEDICAL GROUP INC
11100 Euclid Ave, Cleveland, OH 44106
Other Locations
UNIVERSITY HOSPITALS MEDICAL GROUP INC
29325 Health Campus Dr, Suite 1, Westlake, OH 44145

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: SEA-CD70
Study Phase: Phase 1
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Decitabine, Ipilimumab
Study Phase: Phase 1
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Enrollment Status: Terminated
Publish Date: July 31, 2025
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine, Decitabine, INQOVI
Study Phase: Phase 2
Phase I Clinical Trial of Human AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia)
Phase I Clinical Trial of Human AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia)
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Biological, Drug
Study Drugs: Fully human anti CD19 CAR-T Cell, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies
An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: Venetoclax, Selinexor
Study Phase: Phase 1
Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy
Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy
Enrollment Status: Completed
Publish Date: March 10, 2022
Intervention Type: Drug
Study Drug: Liposomal Annamycin
Study Phase: Phase 1/Phase 2
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Terminated
Publish Date: May 24, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
A Phase 2 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Enrollment Status: Completed
Publish Date: October 17, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

45 Total Publications

Combining drugs that bypass p53 to treat TP53-mutated leukemias.
Combining drugs that bypass p53 to treat TP53-mutated leukemias.
Journal: Blood advances
Published: March 31, 2025
Similar Doctors
Advanced in Acute Intermittent Porphyria
Dr. Alan Lichtin
Hematology
Advanced in Acute Intermittent Porphyria
Dr. Alan Lichtin
Hematology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.6 miles away)
866-223-8100
Experience:
49+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alan Lichtin is a Hematologist in Cleveland, Ohio. Dr. Lichtin has been practicing medicine for over 49 years and is rated as a Distinguished provider by MediFind in the treatment of Acute Intermittent Porphyria. His top areas of expertise are Adult T-Cell Leukemia, Thrombocytopenia, Paroxysmal Cold Hemoglobinuria, Anemia, and Splenectomy.

Advanced in Acute Intermittent Porphyria
Dr. Willem Vanheeckeren
Hematology Oncology
Advanced in Acute Intermittent Porphyria
Dr. Willem Vanheeckeren
Hematology Oncology

Hillcrest Hospital

6780 Mayfield Rd, 
Mayfield Heights, OH 
 (8.9 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Willem Vanheeckeren is a Hematologist Oncology provider in Mayfield Heights, Ohio. Dr. Vanheeckeren is rated as a Distinguished provider by MediFind in the treatment of Acute Intermittent Porphyria. His top areas of expertise are Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Thrombocytopenia, and Bone Marrow Aspiration.

Experienced in Acute Intermittent Porphyria
Dr. John J. Graham
Hematology Oncology | Hematology | Oncology
Experienced in Acute Intermittent Porphyria
Dr. John J. Graham
Hematology Oncology | Hematology | Oncology

Blood And Cancer Center Inc

3695 A Boardman Canfield Rd, 
Canfield, OH 
 (57.2 miles away)
330-533-3040
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

John Graham is a Hematologist Oncology specialist and a Hematologist in Canfield, Ohio. Dr. Graham is rated as an Advanced provider by MediFind in the treatment of Acute Intermittent Porphyria. His top areas of expertise are Pleuropulmonary Blastoma, Familial Pancreatic Cancer, Pancreatic Cancer, and ALK-Positive Non-Small Cell Lung Cancer. Dr. Graham is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tomlinson's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 23 Advanced Conditions
View All 66 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile